MedTrace Logo

Transcrestal Sinus Lift With OSSIX Bone vs BIOSS Collagen

NCT07041411 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-06-27

No results posted yet for this study

Summary

Primary: Histologically analyse the quality of bone regeneration after graft material insertion in severely resorbed maxilla.

Secondary: Radiological analysis of the volume of the bone regenerations with the shirnkage rate of the graft material. clinical study of 20 patients 13 in OSSIX Bone group 13 in Bio-Oss Collagen group all patients requiring a regenerative procedure (sinus lift) having less than 3mm of residual bone height (RBH) with the impossibility to place the implants at the time of regenerative proc 6 months follow up for the first endpoint. (collection of the histological sample) 12 months follow up - long term clinical evaluation. tests performed: Cone Beam Computed Tomography (CBCT), clinical evaluation, X-ray

Conditions

  • Sinus Lift
  • Graft Materials
  • Transcrestal Approach

Interventions

PROCEDURE

maxillary sinus elevation through transcrestal approach using OSSIX® Bone

After a careful radiologic analysis, using a surgical guide, maxillary sinus elevation through transcrestal access to sinus mucosa was achieved. The elevation of the maxillary sinus mucosa was performed through micro-elevators and graft material was inserted.

Sponsors & Collaborators

  • Studio Odontoiatrico Associato Dr. P. Cicchese e L. Canullo

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-10
Primary Completion
2024-05-02
Completion
2025-03-22

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041411 on ClinicalTrials.gov